{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:28:39Z","timestamp":1793734119441,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA244899"],"award-info":[{"award-number":["CA244899"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA244899"],"award-info":[{"award-number":["CA244899"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA246239-01"],"award-info":[{"award-number":["R01 CA246239-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006369","name":"George Mason University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI128949"],"award-info":[{"award-number":["U19 AI128949"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI118610"],"award-info":[{"award-number":["U19 AI118610"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41591-021-01564-7","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:03:17Z","timestamp":1639137797000},"page":"2099-2103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":280,"title":["Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-197X","authenticated-orcid":false,"given":"Oliver","family":"Van Oekelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8884-2100","authenticated-orcid":false,"given":"Adolfo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Upadhyaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schnakenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somali","family":"Gavane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Teruya-Feldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Crary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2699-5555","authenticated-orcid":false,"given":"Mary E.","family":"Fowkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Stacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Kim-Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeeb","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-6730","authenticated-orcid":false,"given":"Joshua D.","family":"Brody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4481-7827","authenticated-orcid":false,"given":"Miriam","family":"Merad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-8469","authenticated-orcid":false,"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"1564_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1564_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.clml.2019.08.002","volume":"19","author":"D Madduri","year":"2019","unstructured":"Madduri, D., Dhodapkar, M. V., Lonial, S., Jagannath, S. & Cho, H. J. SOHO state of the art updates and next questions: T-cell-directed immune therapies for multiple myeloma: chimeric antigen receptor-modified T cells and bispecific T-cell-engaging agents. Clin. Lymphoma Myeloma Leuk. 19, 537\u2013544 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1564_CR3","doi-asserted-by":"crossref","unstructured":"Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985\u20131005 (2020).","DOI":"10.1038\/s41375-020-0734-z"},{"key":"1564_CR4","doi-asserted-by":"publisher","first-page":"m3176","DOI":"10.1136\/bmj.m3176","volume":"370","author":"UA Shah","year":"2020","unstructured":"Shah, U. A. & Mailankody, S. Emerging immunotherapies in multiple myeloma. Brit. Med. J. 370, m3176 (2020).","journal-title":"Brit. Med. J."},{"key":"1564_CR5","doi-asserted-by":"publisher","first-page":"25764","DOI":"10.18632\/oncotarget.25359","volume":"9","author":"DX Bu","year":"2018","unstructured":"Bu, D. X. et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget 9, 25764\u201325780 (2018).","journal-title":"Oncotarget"},{"key":"1564_CR6","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048\u20132060 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1564_CR7","first-page":"2755","volume":"130","author":"P Khattar","year":"2017","unstructured":"Khattar, P. et al. B-cell maturation antigen is exclusively expressed in a wide range of B-cell and plasma cell neoplasm and in a potential therapeutic target for BCMA directed therapies. Blood 130, 2755\u20132755 (2017).","journal-title":"Blood"},{"key":"1564_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727\u2013738 (2012).","journal-title":"Br. J. Haematol."},{"key":"1564_CR9","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","volume":"22","author":"E Sanchez","year":"2016","unstructured":"Sanchez, E. et al. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin. Cancer Res. 22, 3383\u20133397 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1564_CR10","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"YT Tai","year":"2016","unstructured":"Tai, Y. T. et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127, 3225\u20133236 (2016).","journal-title":"Blood"},{"key":"1564_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1564_CR12","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1564_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"1564_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1564_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1564_CR16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/ejh.13380","volume":"104","author":"N Gagelmann","year":"2020","unstructured":"Gagelmann, N., Ayuk, F., Atanackovic, D. & Kroger, N. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis. Eur. J. Haematol. 104, 318\u2013327 (2020).","journal-title":"Eur. J. Haematol."},{"key":"1564_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.clml.2020.04.020","volume":"20","author":"SS Jatiani","year":"2020","unstructured":"Jatiani, S. S. et al. Myeloma CAR-T CRS management with IL-1R antagonist anakinra. Clin. Lymphoma Myeloma Leuk. 20, 632\u2013636 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1564_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature11405","volume":"489","author":"MJ Hawrylycz","year":"2012","unstructured":"Hawrylycz, M. J. et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489, 391\u2013399 (2012).","journal-title":"Nature"},{"key":"1564_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/bjh.14145","volume":"174","author":"L Lee","year":"2016","unstructured":"Lee, L. et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol. 174, 911\u2013922 (2016).","journal-title":"Br. J. Haematol."},{"key":"1564_CR20","doi-asserted-by":"crossref","unstructured":"Shah, U. A. & Mailankody, S. CAR T and CAR NK cells in multiple myeloma: expanding the targets. Best Pract. Res. Clin. Haematol. 33, 101141 (2020).","DOI":"10.1016\/j.beha.2020.101141"},{"key":"1564_CR21","doi-asserted-by":"crossref","unstructured":"Kotecha, N., Krutzik, P. O. & Irish, J. M. Web-based analysis and publication of flow cytometry experiments. Curr. Protoc. Cytom. Chapter 10, Unit10.17 (2010).","DOI":"10.1002\/0471142956.cy1017s53"},{"key":"1564_CR22","unstructured":"Kolde, R. pheatmap: Pretty Heatmaps. Version 1.0.12. https:\/\/rdrr.io\/cran\/pheatmap\/ (2019)."},{"key":"1564_CR23","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis, (Springer-Verlag, 2016).","DOI":"10.1007\/978-3-319-24277-4"},{"key":"1564_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nprot.2015.020","volume":"10","author":"ER Zunder","year":"2015","unstructured":"Zunder, E. R. et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat. Protoc. 10, 316\u2013333 (2015).","journal-title":"Nat. Protoc."},{"key":"1564_CR25","doi-asserted-by":"publisher","first-page":"748","DOI":"10.12688\/f1000research.11622.1","volume":"6","author":"M Nowicka","year":"2017","unstructured":"Nowicka, M. et al. CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. F1000Res 6, 748 (2017).","journal-title":"F1000Res"},{"key":"1564_CR26","doi-asserted-by":"crossref","unstructured":"Weber, L. M. diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering. Commun. Biol. 2, 183 (2019).","DOI":"10.1038\/s42003-019-0415-5"},{"key":"1564_CR27","unstructured":"Crowell, H. L., Zanotelli, V. R. T., Chevrier, S. & Robinson, M. D. CATALYST: Cytometry dATa anALYSis Tools. https:\/\/github.com\/HelenaLC\/CATALYST (2020)."},{"key":"1564_CR28","unstructured":"Ellis, B. et al. flowCore: basic structures for flow cytometry data. https:\/\/www.bioconductor.org\/packages\/devel\/bioc\/manuals\/flowCore\/man\/flowCore.pdf (2019)."},{"key":"1564_CR29","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/cyto.a.22625","volume":"87","author":"S Van Gassen","year":"2015","unstructured":"Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636\u2013645 (2015).","journal-title":"Cytometry A"},{"key":"1564_CR30","doi-asserted-by":"crossref","unstructured":"Kim, H. J., Lin, Y., Geddes, T. A., Yang, J. Y. H. & Yang, P. CiteFuse enables multi-modal analysis of CITE-seq data. Bioinformatics 36, 4137\u20134143 (2020).","DOI":"10.1093\/bioinformatics\/btaa282"},{"key":"1564_CR31","doi-asserted-by":"crossref","unstructured":"Amezquita, R. A. et al. Orchestrating single-cell analysis with Bioconductor. Nat. Methods 17, 137\u2013145 (2019).","DOI":"10.1038\/s41592-019-0654-x"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01564-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:11:01Z","timestamp":1639566661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01564-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01564-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"6 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.V.O. has no relevant conflicts to disclose. A.A. has no relevant conflicts to disclose. B.U. has no relevant conflicts to disclose. S.S. has no relevant conflicts to disclose. S.S. is currently employed by Sema4 but was not working for the company at the time of preparation of the manuscript. D.M. has worked as a consultant for Bristol Myers Squibb, Celgene, Foundation Medicine, GSK, Janssen, Kinevant and Sanofi and has received grant and research support from Allogene, Amgen, Bristol Myers Squibb, Celgene, Janssen and Regeneron. D.M. is currently employed by Johnson & Johnson but was not working for the company at the time of preparation of the manuscript. S.G. has no relevant conflicts to disclose. J.T.F. has no relevant conflicts to disclose. J.F.C. has no relevant conflicts to disclose. C.B.S. is a member of the ciltacabtagene autoleucel Risk Evaluation and Mitigation Strategy advisory board. S.K.S. has no relevant conflicts to disclose. A.R. is currently employed by Immunai but was not working for the company at the time of preparation of the manuscript. A.L. has no relevant conflicts to disclose. J.D.B. has received consulting fees from Celldex, Genentech, Gilead, Janssen, Kite and Merck and has received research funding or reagents provided by Celldex, Genentech, Janssen, Kite and Merck. M.M. has no relevant conflicts to disclose. S.J. has received consulting fees from Bristol Myers Squibb, Janssen, Karyopharm, Merck, Sanofi and Takeda. S.P. receives research funding from Amgen, Celgene\/Bristol Myers Squibb and Karyopharm and consulting fees from Foundation Medicine. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}